Cargando…

HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo

Patients whose NSCLC tumors become afatinib resistant presently have few effective therapeutic options to extend their survival. Afatinib resistant NSCLC cells were sensitive to clinically relevant concentrations of the irreversible pan-HER inhibitor neratinib, but not by the first generation ERBB1/...

Descripción completa

Detalles Bibliográficos
Autores principales:	Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Avogadri-Connors, Francesca, Cutler, Richard E., Lalani, Alshad S., Dent, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685747/ https://www.ncbi.nlm.nih.gov/pubmed/29163826 http://dx.doi.org/10.18632/oncotarget.21660

Ejemplares similares

Correction: HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo
por: Booth, Laurence, et al.
Publicado: (2019)

[Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration
por: Booth, Laurence, et al.
Publicado: (2017)

The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib
por: Booth, Laurence, et al.
Publicado: (2019)

The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib
por: Booth, Laurence, et al.
Publicado: (2017)

HDAC inhibitors enhance the immunotherapy response of melanoma cells
por: Booth, Laurence, et al.
Publicado: (2017)

Axitinib and HDAC Inhibitors Interact to Kill Sarcoma Cells
por: Roberts, Jane L., et al.
Publicado: (2021)

PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide
por: Booth, Laurence, et al.
Publicado: (2016)

PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib]
por: Booth, Laurence, et al.
Publicado: (2017)

The calcium‐sensing receptor: A novel target for treatment and prophylaxis of neratinib‐induced diarrhea
por: Lysyy, Taras, et al.
Publicado: (2019)

The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo
por: Booth, Laurence, et al.
Publicado: (2017)

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer
por: Collins, Denis M., et al.
Publicado: (2019)

Rationally Repurposing Ruxolitinib (Jakafi(®)) as a Solid Tumor Therapeutic
por: Tavallai, Mehrad, et al.
Publicado: (2016)

PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening
por: Lee, Jangsoon, et al.
Publicado: (2021)

Fingolimod Augments Monomethylfumarate Killing of GBM Cells
por: Dent, Paul, et al.
Publicado: (2020)

Corrigendum: Fingolimod Augments Monomethylfumarate Killing of GBM Cells
por: Dent, Paul, et al.
Publicado: (2020)

Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2(+ve) breast cancer metastasis
por: Nagpal, Aadya, et al.
Publicado: (2019)

Neratinib for breast cancer
Publicado: (2019)

Metabolism of Histone Deacetylase Proteins Opsonizes Tumor Cells to Checkpoint Inhibitory Immunotherapies
por: Dent, Paul, et al.
Publicado: (2019)

Transcriptome analysis of neratinib treated HER2 positive cancer model vs untreated cancer unravels the molecular mechanism of action of neratinib
por: Alkhezayem, Sara, et al.
Publicado: (2020)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
por: Veeraraghavan, Jamunarani, et al.
Publicado: (2021)

Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer
por: Ribas, Ricardo, et al.
Publicado: (2018)

Inhibition of heat shock proteins increases autophagosome formation, and reduces the expression of APP, Tau, SOD1 G93A and TDP-43
por: Dent, Paul, et al.
Publicado: (2021)

Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS
por: Tavallai, Mehrad, et al.
Publicado: (2016)

AR12 (OSU-03012) suppresses GRP78 expression and inhibits SARS-CoV-2 replication
por: Rayner, Jonathan O., et al.
Publicado: (2020)

Curcumin interacts with sildenafil to kill GI tumor cells via endoplasmic reticulum stress and reactive oxygen/ nitrogen species
por: Roberts, Jane L., et al.
Publicado: (2017)

Multi-kinase inhibitors interact with sildenafil and ERBB1/2/4 inhibitors to kill tumor cells in vitro and in vivo
por: Booth, Laurence, et al.
Publicado: (2016)

AR12 increases BAG3 expression which is essential for Tau and APP degradation via LC3-associated phagocytosis and macroautophagy
por: Dent, Paul, et al.
Publicado: (2022)

Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer
por: Saura, Cristina, et al.
Publicado: (2021)

Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial
por: Oaknin, Ana, et al.
Publicado: (2020)

Kinase inhibitors: look beyond the label on the bottle
por: Dent, Paul, et al.
Publicado: (2019)

OSU‐03012 and Viagra Treatment Inhibits the Activity of Multiple Chaperone Proteins and Disrupts the Blood–Brain Barrier: Implications for Anti‐Cancer Therapies
por: Booth, Laurence, et al.
Publicado: (2015)

Nexavar/Stivarga and Viagra Interact to Kill Tumor Cells
por: Tavallai, Mehrad, et al.
Publicado: (2015)

Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy
por: Liu, Junjie, et al.
Publicado: (2022)

Neratinib protects pancreatic beta cells in diabetes
por: Ardestani, Amin, et al.
Publicado: (2019)

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial
por: Chia, Stephen K. L., et al.
Publicado: (2019)

Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy
por: Cruickshanks, Nichola, et al.
Publicado: (2013)

Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition
por: Han, Rui, et al.
Publicado: (2023)

The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling
por: Booth, Laurence, et al.
Publicado: (2016)

Profile of neratinib and its potential in the treatment of breast cancer
por: Feldinger, Katharina, et al.
Publicado: (2015)

Neratinib-Induced Duodenal Ulcer: A Case Report
por: Moftakhar, Bahar, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9cifrtles3oiuejrvviur3ce53